Chief Executive
James Barder is the Group’s Chief Executive. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations and leads commercial negotiations. He is also a Non-Executive Director of Caisson IO Group Limited and a Director of the Mary How Trust for Cancer Prevention.
Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James predominantly worked in the field of reinsurance and finance including firms he founded.
Over 30 years of experience in setting up, managing and running companies.
Finance Director, Chief Operating Officer and Company Secretary
Angela Hildreth leads the Group’s finance, HR and IT functions, drives commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.
Senior financial roles in a diverse range of industries, including seven years as UK Finance Director at Shield Therapeutics plc (quoted on AIM). She was also an Independent Non-Executive Director and Chair of the Audit Committee at AIM-listed Aptamer plc.
Over 15 years’ strategic and operational financial experience of developing and commercialising pharmaceutical products.
Executive Director and Head of R&D
Ken James is the Head of R&D. He oversees the development, regulatory, quality and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.
Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Over 40 years’ experience in the research, development and commercialisation of consumer healthcare products.
Non-Executive Chairman
Jeff Needham is Non-Executive Chairman of Futura Medical plc. He was previously a Non-Executive Director of Futura Medical plc since November 2021. He is also a Chair of the Nominations Committee. Jeff is also currently on the Board of McKee Foods Corp.
President of Perrigo Consumer Self-Care Americas (including USA) and Executive Vice President at Perrigo Company plc, the US-based manufacturer and marketer of consumer healthcare products, and a board director of the US Consumer Healthcare Products Association for 11 years.
Over 35 years of experience in manufacturing and marketing of consumer healthcare products with strategic and corporate management expertise, with particular expertise in the US market.
Senior Independent Non-Executive Director
Andrew Unitt is an Independent Non-Executive Director and Chair of the Audit Committee. He is also a member of the Remuneration Committee and the Nominations Committee.
Chief Financial Officer at the University of Nottingham until 2016. Andrew spent eleven years at Boots plc, where he was Managing Director and Finance Director for four years of Boots Healthcare International, its over the counter medicines business. Andrew was also an Independent Non-Executive Director of AIM-listed company Oncimmune Holdings plc.
Over 20 years of experience as a Finance Director in a wide range of industries with strong financial experience and OTC market expertise.
Independent Non-Executive Director
Roy Davis is an Independent Non-Executive Director and Chair of the Remuneration Committee. He is a member of the Audit Committee and the Nominations Committee. He is also a Non-Executive Chair at LungLife AI plc, Foster and Freeman (the trading name of the Galton group of companies), Rair Health Ltd and Inspiration Healthcare Group plc.
Leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc and Gyrus Group plc and Non-Executive Chair at Medica Group plc.
Over 35 years of commercial experience including in medical devices companies and strategic consulting and has a proven track record of successfully scaling companies and delivering substantial value for shareholders.